文献速递分子诊断临床微生物

QIAstat-Dx脑膜炎/脑炎多重PCR面板多中心评估

Multicenter evaluation of the multiplex polymerase chain reaction QIAstat-Dx Meningitis/Encephalitis Panel for the detection of central nervous system pathogens directly in the cerebrospinal fluid.
PubMed 文献 · J Clin Microbiol · 2026-10-27

该多中心研究在欧美13个中心评估QIAstat-Dx脑膜炎/脑炎(ME)面板检测脑脊液中病原体的性能,共测试1667份临床样本。结果显示该面板与BioFire FilmArray ME面板总体阳性符合率为85.4%,分歧解析后升至95.3%,阴性符合率99.9%,支持其作为快速诊断社区获得性ME的可靠全自动多重PCR平台。

要点

  • QIAstat-Dx ME面板与BFME面板总体PPA为85.4%,分歧解析后达95.3%。
  • 对脑膜炎奈瑟菌、肺炎链球菌和无乳链球菌的PPA均为100%。
  • 总体NPA为99.9%,人工阳性样本仅2.3%结果不正确。

核心结论

  • QIAstat-Dx ME面板与BioFire FilmArray ME面板高度一致,可作为快速诊断社区获得性脑膜炎/脑炎的可靠全自动多重PCR平台。

研究设计与样本

  • 多中心研究,在欧美13个中心测试疑似脑膜炎/脑炎患者的脑脊液样本及人工样本,共1667份临床样本(1527份前瞻性、140份存档)。

主要发现

  • 前瞻性样本中QIAstat-Dx ME面板检出病原体115份(7.5%),包括肺炎链球菌(1.1%)、流感嗜血杆菌(0.5%)、单核细胞增生李斯特菌(0.3%)等。
  • 与BFME面板比较(n=1664),总体PPA为85.4%,分歧解析后升至95.3%。
  • 对脑膜炎奈瑟菌、肺炎链球菌和无乳链球菌的PPA均为100%。
  • 总体NPA为99.9%。
  • 1154份人工阳性样本中仅27份(2.3%)结果不正确。

临床怎么用

  • 该面板可与标准诊断方法联合使用,有望改善早期诊断、指导靶向治疗并支持疑似脑膜炎/脑炎患者的有效临床管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rapid and accurate detection of pathogens causing meningitis/encephalitis (MEN/EN) is critical to improving clinical outcomes. Multiplex polymerase chain reaction (PCR) enables simultaneous detection of multiple pathogens from the cerebrospinal fluid (CSF), offering advantages over traditional methods. This multicenter study evaluated the performance of the QIAstat-Dx Meningitis/Encephalitis (ME) Panel versus conventional methods, including the BioFire FilmArray ME (BFME) Panel. The CSF samples from patients with suspected MEN/EN along with contrived samples were tested across 13 sites in Europe/USA. Positive percent agreement (PPA) and negative percent agreement (NPA) between the QIAstat-Dx ME Panel and comparator methods were determined. A total of 1,667 clinical samples (1,527 prospective, 140 archived) were tested. Pathogens were detected by the QIAstat-Dx ME Panel in 115 (7.5%) prospective samples, including Streptococcus pneumoniae (1.1%), Haemophilus influenzae (0.5%), Listeria monocytogenes (0.3%), S. agalactiae (0.2%), Escherichia coli K1 (0.1%), Neisseria meningitidis (0.1%), S. pyogenes (0.1%), enterovirus (1.5%), human herpesvirus-6 (1.0%), herpes simplex virus-2 (0.9%) and -1 (0.3%), varicella zoster virus (0.7%), cytomegalovirus (0.3%), human parechovirus (0.3%), and Cryptococcus gattii/neoformans (0.4%). Overall PPA versus BFME (n = 1,664) was 85.4%, increasing to 95.3% after discordance resolution. PPA was 100% for N. meningitidis, S. pneumoniae, and S. agalactiae. Overall NPA was 99.9%. Among 1,154 contrived positive samples, only 27 (2.3%) incorrect results were observed. The QIAstat-Dx ME Panel demonstrated high concordance with BFME, supporting its use as a reliable, fully automated multiplex PCR platform for rapid diagnosis of community-acquired MEN/EN.IMPORTANCEThis multicenter study demonstrated that the QIAstat-Dx ME Panel delivers clinical performance comparable to that of the BioFire FilmArray ME (BFME) Panel, supporting its validity as a reliable syndromic molecular diagnostic tool for MEN/EN. With its broad pathogen coverage, rapid turnaround time (TAT), and the ability to provide amplification curves and Ct values, the QIAstat-Dx ME Panel offers a valuable option for broad and timely detection of bacterial, viral, and fungal CNS pathogens. When used alongside the SoC diagnostic methods, this panel has the potential to improve early diagnosis, guide targeted therapy, and support effective clinical management of patients with suspected MEN/EN.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Farnsworth C, Ren P, González-López JJ, et al. Multicenter evaluation of the multiplex polymerase chain reaction QIAstat-Dx Meningitis/Encephalitis Panel for the detection of central nervous system pathogens directly in the cerebrospinal fluid. J Clin Microbiol. 2026. PMID: 42937305. doi:10.1128/jcm.00738-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。